Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Urinary Bladder, Overactive

• Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity
• Management of OAB in Female Patients .
• A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)
• Acupuncture Combined With Mirabegron in the Treatment of OAB
• Effectiveness of Oral Boldo in Women With Overactive Bladder
• Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder
• Xeomin vs Botox for Treatment of Overactive Bladder Syndrome
• Study of V117957 in Overactive Bladder Syndrome
• Prostate Enucleation With Intravesical Botox Injections in Treating BPH and Bladder Overactivity
• Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls
• Examining the Effects of Intra-detrusor Botulinum Toxin at Time of Holmium Laser Enucleation of the Prostate (HoLEP) in Men With Overactive Bladder (OAB) Symptoms
• Efficacy of Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder
• Lidocaine Patches Prior to Percutaneous Nerve Evaluation
• Effect of Mirabegron on Bladder Compliance
• Single-Dose Versus Multi-Dose Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection
• Efficacy and Safety of High Dose Vitamin D Supplementation for Overactive Bladder Dry in Children
• A Study of Mirabegron in Young Children With Neurogenic Detrusor Overactivity
• Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks
• Reduced-dose Botox for Urgency Incontinence Among Elder Females: A Mixed-methods Randomized Controlled Trial
• Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB
• A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC
• Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder
• Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study
• The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder
• The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder
• TReating Incontinence for Underlying Mental and Physical Health
• Intradetrusor Botulinum Toxin A: Are Less Injections Better?
• A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder
• Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome
• Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children
• Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome
• Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial
• Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial
• Using Oral Valacyclovir to Treat Patients With Refractory IC/BPS
• Composur: Study to Understand the Performance of Vibegron in Participants With Overactive Bladder (OAB)
• To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder
• The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers
• Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder
• Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
• Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis
• BOTOX® at the Time of Prolapse Surgery for OAB
• A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
• A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
• Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB)
• Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.
• Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.
• A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Process
• A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.
• BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG
• Efficacy of Biofeedback PFMT and Medication in Women With Overactive Bladder
• Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched
• Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function
• Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulati
• Antibiotic Prophylaxis for Bladder Botox
• Efficacy of Li-SWT on Persistent Storage Symptoms After Transurethral Surgery for BPO
• Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants
• Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms
• NOGO for an Overactive Bladder
• Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A
• Minimizing Pain During Office Intradetrussor Botox Injection
• Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants
• URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
• Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder
• Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?
• Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder
• Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
• Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin
• Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
• Oxybutynin for Post-surgical Bladder Pain and Urgency
• Fall Prevention in Older Adults With OAB
• Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
• Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
• Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin
• Oral vs Intravesical Analgesia for Office Bladder Botox Injections
• Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome
• Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP
• A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)
• An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
• Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.
• A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder
• Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder
• Trigonal vs Non Trigonal Botox Injection in OAB.
• Herbal Patch for Overactive Bladder
• OnabotulinumtoxinA Bladder Injection Study
• Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection
• A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
• Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury
• Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women
• Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome
• Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease
• Lidocaine for Pain After Urodynamic Testing
• Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder
• BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence
• Efficacy Comparison Between Different Management Strategies for Consistent OAB in Patients With SVMs After Surgery
• Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing
• Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.
• Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury
• Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
• Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder
• Study of ONO-8577 in Patients With Overactive Bladder
• Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder
• Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
• Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB
• Evaluation of Botulinum Toxin A Alone Versus Botulinum Toxin A With Hydrodistension for Treatment of Overactive Bladder
• Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers
• Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects
• Mirabegron For Erectile Dysfunction
• Timing of B and O Suppositories to Help Relieve Post-operative Bladder Spasms
• Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity
• Investigation of the Effect of the Female Urinary Microbiome on Incontinence
• A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects
• Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder
• Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer
• A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB)
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
• Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity
• Instillation of Botox in the Bladder in Women With Overactive Bladder (OAB)
• Comparison of Electrical Pudendal Nerve Stimulation and Tolterodine Tartrate for Urgency-Frequency Syndrome in Women
• Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms
• Urinary Biomarkers in Overactive Bladder in Children
• Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")
• Reproducibility Study of OABSS and Its Response to Treatment
• Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2
• Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
• A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
• Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists
• Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.
• Reduction of Bladder Injection Pain With Belladonna Opiate Suppository
• Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease
• Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
• Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes
• Mirabegron in Parkinson Disease and Impaired Cognition
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
• The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides
• Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use
• Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.
• Mirabegron and Urinary Urgency Incontinence
• The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.
• Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB
• Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder
• Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder
• Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.
• Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement
• Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Efficacy Study
• Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers
• A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
• Fesoterodine on Urgency Episodes in Parkinson's Disease Population
• MIrabegron With oveRACtive bLadder Symptoms in mEn
• Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children
• A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice
• Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI
• Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
• Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.
• A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment
• Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
• Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin
• Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women
• A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
• Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility
• Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder
• A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)
• A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics
• Oxybutynin and Omega-3 for OAB (Overactive Bladder)
• A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
• Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome
• Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity
• A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
• This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
• OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
• Drug Use Investigation for Toviaz
• Validation of Instruments for Pragmatic Clinical Trials for Overactive Bladder
• The Effect of Anticholinergics on Cognitive Function in the Elderly
• Drug Use-Results Survey of Betanis Tablets in Japan
• A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
• Long-Term Specified Drug Use-results Survey of Betanis Tablets
• Specified Drug Use-results Survey of Betanis Tablets
• Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients
• Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer
• Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
• Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women
• Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome
• Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome)
• Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity
• VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate
• A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
• Management of the Idiopathic Overactive Bladder With Botulinum Toxin: Systematic Review
• Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)
• A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
• A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)
• Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
• Prevention of Bladder Dysfunction in Acute Spinal Cord Injury
• A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy
• Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome
• A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076
• Bacterial Genomic Sequencing in Overactive Bladder
• A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder
• Vesitirim™ in Men Postmarketing Observational Study
• A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
• A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)
• Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug
• Premarin Versus Toviaz for Treatment of Overactive Bladder
• Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate
• Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
• Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions
• Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms
• Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder
• A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers
• A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug
• A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
• Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder
• The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB)
• Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity
• Pharmacokinetics and Relative Bioavailability Study
• Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder
• Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome
• Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
• A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)
• Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients
• Post Marketing Survey of Vesicare in Japan
• Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
• Efficacy and Safety of Gabapentin in Treating Overactive Bladder
• A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
• Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
• Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
• Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms
• Comparative Urine Proteomic Studies of Overactive Bladder in Humans
• A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
• A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment
• A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
• Therapy of the Overactive Bladder Syndrome
• Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder
• A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine
• A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.
• Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency
• This Is A Study Of Bioavailability And Food Effect For Fesoterodine.
• Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents
• Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder
• Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
• Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
• Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain
• Behavioral Treatment of Overactive Bladder in Men
• Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
• Combined Behavioral and Drug Treatment of Overactive Bladder in Men
• Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome
• Anticholinergic vs. Botox Comparison Study
• Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence
• Bryophyllum Versus Placebo for Overactive Bladder
• A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment
• Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
• Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity
• Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
• Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder
• OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER
• A Study of YM178 in Subjects With Symptoms of Overactive Bladder
• Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease
• A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder
• Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder
• Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
• Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients
• Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency
• A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
• This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder
• Trospium Chloride XR in Obese Female Patients With Overactive Bladder
• A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
• Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)
• FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period
• The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
• A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
• A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
• The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects
• Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
• Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
• Validation of a Real-time Urodynamic Measure of Urinary Urgency
• Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder
• A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects
• Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients
• A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects
• Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease
• A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks
• Microorganism in Overactive Bladder Patients
• Toviaz Post Marketing Surveillance Study
• Study of ONO-8539 in Patients With Overactive Bladder
• Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
• Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
• Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
• A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects
• Over Active Bladder Patients Having Sling Surgery
• Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity
• A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients
• Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder
• Botulinum A Toxin in Patients With Parkinson's Disease
• Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder
• A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031
• UK Study Assessing Flexible Dose Fesoterodine in Adults
• Solifenacin Succinate Versus Tolterodine 4mg Once Daily
• Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms
• Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity
• A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
• Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder
• Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).
• Post Marketing Surveillance Study on Emselex After Launch in Germany
• A Safety Extension Study of DR-OXY-301
• Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder
• Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder
• Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia
• A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
• Feasibility of "At-home" Titration of Solifenacin
• Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder
• A Phase II Study of KUC-7483 in Patients With Overactive Bladder
• Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients
• 2 Week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Yrs) With Neurogenic Detrusor Overactivity
• A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder
• Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy
• Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
• Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
• A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder
• A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis
• Over Active Bladder Instillation Study - Botox
• A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
• Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.
• Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity
• A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring
• A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.
• An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants
• Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.
• Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence
• Botulin-A Toxin Instillations and Overactive Bladder
• Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
• Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life
• SSR240600C Treatment in Women With Overactive Bladder
• Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.
• The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder
• InSite for Over Active Bladder
• Fesoterodine "add-on" Male Overactive Bladder Study
• Fesoterodine Flexible Dose Study
• A Study of YM178 in Patients With Symptomatic Overactive Bladder
• Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder
• SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
• A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder
• Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity
• Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.
• This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.
• Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder
• A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function
• Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms
• Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms
• A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)
• Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder
• Overactive Bladder Innovative Therapy Trial (OrBIT)
• Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)
• Safety And Efficacy Of Solifenacin In Men With Overactive Bladder (OAB) And Detrusor Underactivity
• ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
• Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
• Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)
• Local Anesthetic Treatments for Overactive Bladder
• A Two-Part Study to Determine: Best Medication Formulation and Food Effect
• A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients
• SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
• A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients
• Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
• A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
• Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms
• A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)
• A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)
• Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity
• Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients
• A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
• Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome
• Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder
• Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)
• Detrol LA In Men With Overactive Bladder.
• Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach.
• A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)
• Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder.
• Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.
• Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder
• Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome
• Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase
• Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
• A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
• NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder
• Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan
• Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan
• Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder
• A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder
• MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.
• Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
• A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
• A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder
• A Research Study for Patients With Overactive Bladder
• Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women
• Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
• A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder
• Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder